著者
Cheng Yang Jun Teng Chao Ning Wenwen Wang Shuai Liu Qin Zhang Dan Wang Hui Tang
出版者
Japan Poultry Science Association
雑誌
The Journal of Poultry Science (ISSN:13467395)
巻号頁・発行日
pp.0210138, (Released:2022-05-25)
被引用文献数
2

Body measurement traits (BMTs), which are classical quantitative traits of vital responses to body growth, have been studied in pigs, cattle, and sheep for several decades. In chickens, BMTs mainly cover body slope length, keel length, chest width, chest depth, tibia length, and tibia diameter; however, their genetic markers are yet to be considered. In this study, the Wenshang Barred chicken, a meat-egg-type native breed in China, was used to investigate the association between BMTs and the expression of growth-related genes, including GH, IGF1, IGF2, GHRL, IGF1R, IGFBP2, GHF-1, and TSHB. The results revealed that the single nucleotide polymorphism (SNP) rs3138025 in GH was significantly associated with keel length (P = 0.0455 < 0.05), rs313810945 in IGF2 was significantly correlated with chest width (P = 0.0454 < 0.05) and chest depth (P = 0.0259 < 0.05), and rs317298536 in TSHB significantly affected chest depth (P = 0.0399 < 0.05). The SNPs were associated with traits reflecting body size and were potentially involved in bone growth, which was consistent with studies in humans, rodents, and other vertebrate species. In addition, a borderline significant association was found between rs317298536 and body weight (P = 0.0604). These polymorphic sites may be treated as candidate genetic markers in breeding programs involving Wenshang Barred chickens.
著者
Wenwen Wang Zijia Zhang Yanping Deng Zhixin Yang Jinjun Hou Huali Long Min Lei Wanying Wu
出版者
International Research and Cooperation Association for Bio & Socio-Sciences Advancement
雑誌
BioScience Trends (ISSN:18817815)
巻号頁・発行日
pp.2021.01140, (Released:2021-06-26)
参考文献数
41
被引用文献数
1

Enhancement of alternative activation (M2) in microglia is a promising therapeutic target for microglia-mediated neuroinflammation. Shenqi Fuzheng Injection (SFI) is a clinical adjuvant treatment for cancer to reduce the side effects during cancer treatment, including boosting mood and improving appetite. However, the mechanism of SFI's effects on central symptoms is not clear. Therefore, using arginase 1 (Arg1) and transforming growth beta-1 (Tgfb1) as markers for M2 microglia activation, we found that compounds 1, 5, 12, 14, and 15 are the major M2-promoting constituents in SFI, which significantly upregulated Arg1 or Tgfb1 gene expression. Our results suggested that these compounds in SFI may promote M2 microglial activation and have potential uses in modulating microglial activation and alleviating neuroinflammation.